GLSH Stock Overview
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Gelesis Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.012 |
| 52 Week High | US$0.55 |
| 52 Week Low | US$0.0082 |
| Beta | 1.96 |
| 1 Month Change | -75.83% |
| 3 Month Change | -76.71% |
| 1 Year Change | -96.89% |
| 3 Year Change | -99.88% |
| 5 Year Change | n/a |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLSH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.8% | -1.9% | -2.8% |
| 1Y | -96.9% | -5.7% | 24.1% |
Return vs Industry: GLSH underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: GLSH underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| GLSH volatility | |
|---|---|
| GLSH Average Weekly Movement | 30.7% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLSH's share price has been volatile over the past 3 months.
Volatility Over Time: GLSH's weekly volatility has decreased from 46% to 31% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 93 | Yishai Zohar | www.gelesis.com |
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation.
Gelesis Holdings, Inc. Fundamentals Summary
| GLSH fundamental statistics | |
|---|---|
| Market cap | US$850.69k |
| Earnings (TTM) | -US$51.67m |
| Revenue (TTM) | US$12.14m |
0.1x
P/S Ratio0.0x
P/E RatioIs GLSH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLSH income statement (TTM) | |
|---|---|
| Revenue | US$12.14m |
| Cost of Revenue | US$19.59m |
| Gross Profit | -US$7.45m |
| Other Expenses | US$44.21m |
| Earnings | -US$51.67m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | -61.40% |
| Net Profit Margin | -425.58% |
| Debt/Equity Ratio | -325.5% |
How did GLSH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/30 06:57 |
| End of Day Share Price | 2023/10/30 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gelesis Holdings, Inc. is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Grosslight | Citigroup Inc |